Skip to main content

Longeveron, Inc. (LGVN)

NASDAQ: LGVN · IEX Real-Time Price · USD
19.58
-0.67 (-3.31%)
At close: Dec 7, 2021 4:00 PM
19.55
-0.03 (-0.15%)
After-hours:Dec 7, 2021 7:59 PM EST
Market Cap397.28M
Revenue (ttm)2.28M
Net Income (ttm)-14.33M
Shares Out20.29M
EPS (ttm)-0.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,040,423
Open20.04
Previous Close20.25
Day's Range18.63 - 21.47
52-Week Range2.84 - 45.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateNov 12, 2021

About LGVN

Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypo...

IndustryBiotechnology
IPO DateFeb 12, 2021
Employees12
Stock ExchangeNASDAQ
Ticker SymbolLGVN
Full Company Profile

Financial Performance

Financial Statements

News

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared f...

7 hours ago - InvestorPlace

2 Big Stock Bets That Are Insiders Are Buying Now

Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy.

Other symbols:CNTA
1 day ago - InvestorPlace

Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome...

MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and ce...

1 day ago - GlobeNewsWire

Why Longeveron Stock Skyrockted 661.2% in November

The biotech stock is now up 171.5% year to date.

2 days ago - The Motley Fool

Is Longeveron a Good Biotech Stock to Buy?

Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.

2 days ago - The Motley Fool

Longeveron Inc. Announces Closing of a $20.5 Million Private Placement

MIAMI, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and li...

4 days ago - GlobeNewsWire

Hot Stocks To Buy Right Now? 3 Health Care Stocks To Know

Health care stocks seem to be in vogue again as the Omicron Covid variant spreads globally.

Other symbols:GSKMRK
4 days ago - Stockmarketcom

Here's Why Longeveron Is Surging Today

An orphan drug designation for the treatment of a rare heart condition is pushing the biotech stock higher.

4 days ago - The Motley Fool

Longeveron Shares Gain After Lead Product Gets FDA Orphan Drug Tag For Type Of Congenital Heart Defect

The FDA has granted Orphan Drug designation to Longeveron Inc's (NASDAQ: LGVN) lead investigational product Lomecel-B for Hypoplastic left heart syndrome (HLHS). Lomecel-B is a cell-based therapy produc...

4 days ago - Benzinga

Longeveron Shares Fall After Raising $20M Capital Via Equity

Longeveron Inc (NASDAQ: LGVN) has announced a private placement of approximately $20.5 million of its common stock and warrants. The purchase price for one share of common stock and one corresponding wa...

6 days ago - Benzinga

Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement

MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and li...

6 days ago - GlobeNewsWire

Longeveron Announces Clinical Collaboration To Study Cell Therapy Aging Treatment In Japan: Why It Matters

Longeveron Inc. (NASDAQ: LGVN) announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B. What Happened: Florida-based Longeverson said it has entered into a spo...

1 week ago - Benzinga

Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients

New trial is in collaboration with Japan's National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital New trial is in collaboration with Japan's National Center for Geriatric...

1 week ago - GlobeNewsWire

Even After a Blistering Rally, Longeveron Is Still Buyable

LGVN stock is speculative and Longeveron's fiscal performance has some sticking points. Still, an FDA approval could propel the stock higher.

1 week ago - InvestorPlace

4 Hot Health Care Stocks To Watch Right Now

Could rising coronavirus cases globally see these health care stocks be put back into the limelight?

Other symbols:MRKNVAXTDOC
1 week ago - Stockmarketcom

Why Longeveron Stock Is Skyrocketing Today

A short squeeze appears to be underway.

1 week ago - The Motley Fool

LGVN Stock: 7 Things to Know as Longeveron Rockets 100% Higher

Today, investors in Longeveron are once again seeing tremendous upside momentum as LGVN stock surges another 80%. The post LGVN Stock: 7 Things to Know as Longeveron Rockets 100% Higher appeared first o...

1 week ago - InvestorPlace

4 Biotech Stocks To Watch This Week

Could these biotech stocks be poised for long-term gains?

Other symbols:BMRNBNTXRCUS
2 weeks ago - Stockmarketcom

Longeveron up 100% after FDA approves its Lomecel-B medical product

Longeveron Inc (NASDAQ: LGVN) is a clinical biotech firm that develops cellular therapies to treat life-threatening and aging-related conditions. It announced that it had received approval from the FDA ...

2 weeks ago - Invezz

Why Did Longeveron's Stock Just Spike?

Biotechnology player Longeveron Inc. ( LGVN , Financial) more than doubled in value from a single trading session after a major U.S. FDA announcement. The clinical-stage biotech player, which is engaged...

2 weeks ago - GuruFocus

Do These Top Penny Stocks Have Upside Potential in November?

Add these penny stocks to your November watchlist The post Do These Top Penny Stocks Have Upside Potential in November? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:EXPRMETX
2 weeks ago - PennyStocks

LGVN Stock Alert: The Huge FDA News Sending Longeveron to the Moon Today

Today, the FDA has smiled on Longeveron, with investors in LGVN stock seeing absolutely astronomical gains of more than 180% this morning. The post LGVN Stock Alert: The Huge FDA News Sending Longeveron...

2 weeks ago - InvestorPlace

Why Are Longeveron Shares Skyrocketing On Thursday?

The FDA has granted Rare Pediatric Disease (RPD) designation for Longeveron Inc's (NASDAQ: LGVN) Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS). HLHS is a rare and life-threatening congenital hear...

2 weeks ago - Benzinga

U.S. Food and Drug Administration Approves Longeveron's Lomecel-B for Rare Pediatric Disease Designation to Treat Lif...

Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per year Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects ...

2 weeks ago - GlobeNewsWire

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Longeveron to hold conference call today at 8:30 AM EST Longeveron to hold conference call today at 8:30 AM EST

3 weeks ago - GlobeNewsWire